Teva Pharmaceuticals USA, Inc.
Teva Pharmaceuticals USA, Inc. received $31.0M in federal prime contract obligations in the 12 months ending Oct 5, 2026, down 22.8% from $40.2M the year before, and $181.5M since FY2022. Its largest customer is the Department of Defense.
Contractor details
- Unique Entity ID (UEI)
- NEN9A34LRHJ5
- CAGE code
- 3V8D7
- Headquarters
- North Wales, PA
- Business size
- Other Than Small Business
As recorded on this UEI's most recent prime contract action in USAspending.gov. Confirm current registration and certifications in SAM.gov.
Obligations by fiscal year
Net prime contract obligations by federal fiscal year.
Markets where it ranks top 10
Agency and NAICS markets where this UEI is one of the ten largest primes in the latest 12 months.
Top agencies
Funding agencies ranked by obligations since FY2022.
| Funding agency | Latest 12 mo | Since FY2022 |
|---|---|---|
| Department of Defense | $31.0M | $181.5M |
Top NAICS codes
Industry codes agencies recorded on this contractor's awards, since FY2022.
| NAICS | Industry | Latest 12 mo | Since FY2022 |
|---|---|---|---|
| 325412 | Pharmaceutical Preparation Manufacturing | $31.0M | $181.5M |
What it sells
Product and service codes (PSC) on this contractor's awards, since FY2022.
| PSC | Description | Since FY2022 |
|---|---|---|
| 6505 | Drugs and Biologicals | $181.5M |
Recent awards
This contractor's newest prime contract awards, most recent first.
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| SPE2DP26F6513 | Department of Defense 8512183379!ADENOVIRUS TYPE 4 A | $1.2M | Jun 16, 2026 |
| SPE2DP26F6514 | Department of Defense 8512183483!ADENOVIRUS TYPE 4 A | $1.0M | Jun 16, 2026 |
| SPE2DP26F6518 | Department of Defense 8512183579!ADENOVIRUS TYPE 4 A | $687K | Jun 16, 2026 |
| SPE2DP26F6530 | Department of Defense 8512184053!ADENOVIRUS TYPE 4 A | $515K | Jun 16, 2026 |
| SPE2DP26F6515 | Department of Defense 8512183485!ADENOVIRUS TYPE 4 A | $515K | Jun 16, 2026 |
| SPE2DP26F6531 | Department of Defense 8512184059!ADENOVIRUS TYPE 4 A | $344K | Jun 16, 2026 |
| SPE2DP26F6516 | Department of Defense 8512183571!ADENOVIRUS TYPE 4 A | $344K | Jun 16, 2026 |
| SPE2DP26F6517 | Department of Defense 8512183572!ADENOVIRUS TYPE 4 A | $344K | Jun 16, 2026 |
Prime contracts (award types A–D) from USAspending.gov through Oct 5, 2026. Subcontracts are not included. Net obligations include deobligations and corrections.
Ready to connect your pursuit work?
GovEagle gives BD directors, capture managers, and proposal teams one AI workspace from pipeline through proposal, with CMMC/FedRAMP Certified compliance built in.